drugset / Trial / NCT01520298

Intravenous Acetaminophen as Adjuvant Therapy for Pain Control in Geriatric Hip Fracture Patients

NCT01520298 ↗

Phase 3 Withdrawn Lancaster General Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This research study is a prospective, randomized, blinded, placebo controlled trial evaluating the benefit of IV acetaminophen (Ofirmev™) as adjuvant analgesia in geriatric hip fracture patients. IV acetaminophen has received FDA approval. IV acetaminophen does not have the liver toxicity as oral acetaminophen. No oral acetaminophen will be administered. All patients diagnosed with a hip fracture aged at least 65 years and expected to undergo surgical intervention are eligible to participate. Hip fractures affect greater than 300,000 geriatric patients annually, representing the second leading cause of hospitalization for this patient population. Pain control in these patients is often problematic due to co-morbidities and changes in their pharmacokinetic and pharmacodynamic profiles. Subjects may receive the normal DVT prophylactic treatments post-op.

Timeline

Start
2011-12
Primary completion
2013-05
Completion
2013-05

Outcome

Outcome not reported

Stopped (Enrollment): “Difficulty in recruiting subjects for the trial.”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule 1000 mg Intravenous

Indications

No indication recorded.